![[ Beasley Allen Law Firm Logo ]](http://www.mesothelioma.law.pro/wp-content/themes/system-unity/images/logo.png){kind=logo}
Success of lung cancer drug Alimta causes bump in stock price for Lilly
A recent report on Forbes.com said clinical trials are validating the success of the drug Alimta in treating patients with non-small cell lung cancer, providing hope for cancer patients and a jump in stock prices for the drug’s manufacturer, Eli Lilly and Co. The drug also has been approved as a treatment for mesothelioma.
